Autopsy report · NCT04993443

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

“Copmeletion of Part A SAD cohorts, sponsor cancelled Part B-D cohorts”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Syneos Health

Sponsor type

University, hospital or other

Conditions

Asthma

Interventions

LQ036; Matching Placebo

Participants

40

Sites

2

Countries

Australia

Trials that died the same way

• Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants
  “Cohorts 1 and 2 were completed. Cohort 3 was cancelled because it was no longer necessary based on information from another study. No safety concerns were noted.” (59% match in meaning)
• Assessment of Microcirculatory Dysfunction in Septic Shock Patients by OCTA
  “Completed the case-control study (30 patients and 30 controls). The prospective cohort component was discontinued due to slow recruitment and funding constraints.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.